Sales and profits from GLP-1 weight-loss and diabetes drugs like Ozempic and Wegovy are already huge. They're only going to get bigger. Eli Lilly's (NYSE: LLY) GLP-1 drug tirzepatide, which is marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, dethroned Merck's (NYSE: MRK) cancer drug Keytruda last year to become the world's best-selling drug. Novo Nordisk's (NYSE: NVO) sales of the GLP-1 drugs Wegovy and Ozempic pushed the drug manufacturer's market cap above the GDP of its home country, Denmark.
CryptoAlerta — análise de criptomoedas e mercado em tempo real